| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 121.5 | 67.5 |
| Profit before tax | -21.7 | -93.7 |
| Net income | -22.3 | -91.3 |
| EPS (diluted, $ a share) | $-0.05 | $-0.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +80.1% |
|---|---|
| Operating margin | -19.7% |
10-Q filed with the SEC, NASDAQ: IOVA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Iovance Biotherapeutics, Inc.: key numbers
- Share price
- $7.55Close, Nov 16
- Market cap
- $3.49B
- Shares outstanding
- 462.66MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iovance Biotherapeutics, Inc.
All →Iovance Biotherapeutics Investor Presentation
Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The November 2026 presentation provides a corporate overview and updates on the company's cell therapy pipeline and commercialization efforts.
Iovance Biotherapeutics Earnings Call: Key Takeaways
Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.
- Call
- Nov 5, 2026, 8:30 AM ET
Iovance Biotherapeutics Financial Results
Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.
- Term
- Q3 2026
“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
Iovance Biotherapeutics Clinical Trial Data
Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.
Iovance Biotherapeutics Investor Presentation
Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The presentation provides a corporate overview and strategic update as of October 2026.
Iovance Biotherapeutics Investor Meeting
Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from the previous range of $350 million to $370 million. The increase is driven by strong U.S. demand for its cancer therapies Amtagvi and Proleukin, representing approximately 60% annual growth.